1. Home
  2. HUBC vs CANF Comparison

HUBC vs CANF Comparison

Compare HUBC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HUBC
  • CANF
  • Stock Information
  • Founded
  • HUBC 2017
  • CANF 1994
  • Country
  • HUBC Israel
  • CANF Israel
  • Employees
  • HUBC N/A
  • CANF N/A
  • Industry
  • HUBC
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • HUBC
  • CANF Health Care
  • Exchange
  • HUBC Nasdaq
  • CANF Nasdaq
  • Market Cap
  • HUBC 16.0M
  • CANF 14.4M
  • IPO Year
  • HUBC N/A
  • CANF N/A
  • Fundamental
  • Price
  • HUBC $0.53
  • CANF $2.36
  • Analyst Decision
  • HUBC
  • CANF Strong Buy
  • Analyst Count
  • HUBC 0
  • CANF 2
  • Target Price
  • HUBC N/A
  • CANF $14.00
  • AVG Volume (30 Days)
  • HUBC 697.2K
  • CANF 114.9K
  • Earning Date
  • HUBC 10-15-2024
  • CANF 11-15-2024
  • Dividend Yield
  • HUBC N/A
  • CANF N/A
  • EPS Growth
  • HUBC N/A
  • CANF N/A
  • EPS
  • HUBC N/A
  • CANF N/A
  • Revenue
  • HUBC $42,657,000.00
  • CANF $667,000.00
  • Revenue This Year
  • HUBC N/A
  • CANF $356.93
  • Revenue Next Year
  • HUBC N/A
  • CANF N/A
  • P/E Ratio
  • HUBC N/A
  • CANF N/A
  • Revenue Growth
  • HUBC N/A
  • CANF N/A
  • 52 Week Low
  • HUBC $0.44
  • CANF $1.81
  • 52 Week High
  • HUBC $9.40
  • CANF $4.69
  • Technical
  • Relative Strength Index (RSI)
  • HUBC 47.35
  • CANF 60.97
  • Support Level
  • HUBC $0.49
  • CANF $1.87
  • Resistance Level
  • HUBC $0.67
  • CANF $2.04
  • Average True Range (ATR)
  • HUBC 0.06
  • CANF 0.17
  • MACD
  • HUBC 0.00
  • CANF 0.04
  • Stochastic Oscillator
  • HUBC 37.82
  • CANF 72.06

About HUBC Hub Cyber Security Ltd.

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: